Pharmaceutical companies are increasing their spending on lobbying firms connected to President Trump's administration, particularly through firms like Checkmate Government Relations, Miller Strategies, and Ballard Partners, as they navigate potential regulatory changes under Trump's second term. This trend highlights the growing influence of politically connected lobbyists in shaping the pharmaceutical industry’s interactions with government policies. Content creators should note the significant role of political connections in lobbying efforts and their impact on industry regulations.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views7
Tags
Ali NematiBlogUI.author_articles
